| |
|
|
|
|
|
 |
| |
|
·Î¸ÞÇÁ·Ð¾È°úÀ̰ú¿ë¾×(¿°»ê·Î¸ÞÇ÷ϻç½Å) LOMEFLON EYE.[Lomefloxacin HCl]
|
Àü¹®ÀǾàǰ | »èÁ¦
|
|
|
¼öÀÔÀǾàǰ
|
| |
 |
¾Ë¸²: |
µå·°ÀÎÆ÷¿¡¼´Â ÀǾàǰ ÀÎÅÍ³Ý ÆÇ¸Å¸¦ ÇÏÁö ¾Ê½À´Ï´Ù. |
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
À¯·áȸ¿ø °áÀç½Ã¿¡´Â º¸´Ù ´Ù¾çÇÑ ¾à¹°Á¤º¸¸¦
ÀÌ¿ëÇÏ½Ç ¼ö ÀÖ½À´Ï´Ù.
À¯·áÁ¤º¸¸ñ·ÏÀº Àü¹®È¸¿øÀ¸·Î
·Î±×ÀÎ ÇϽøé È®ÀÎ °¡´ÉÇÕ´Ï´Ù.
|
|
|
 | Çã°¡Á¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
û±¸ÄÚµå(KDÄÚµå) ºñ±Þ¿©Á¡°ËÄÚµå »óÇÑ±Ý¾× |
644900760[E02690351]
[º¸ÇèÄڵ忡 µû¸¥ ¾àǰ±âº»Á¤º¸ Á÷Á¢Á¶È¸]
\0 ¿ø/1ml(2012.03.01)(ÇöÀç¾à°¡)
\1,199 ¿ø/1ml(2011.07.01)(º¯°æÀü¾à°¡)
[»óº´ÄÚµåÁ¶È¸]
[Áúº´ÄÚµåÁ¶È¸]
|
| ºü¸¥Á¶È¸ |
|
| Á¦Ç°¼º»ó |
´ã°¥»öÀÇ Åõ¸íÇÑ ÇÃ¶ó½ºÆ½ ¿ë±â¿¡ µç ¹«»öÅõ¸íÇÑ ¾× [Á¦ÇüÁ¤º¸ È®ÀÎ] |
| Æ÷À塤À¯Åë´ÜÀ§ |
3mg/mL¡¿5mL¡¿10EA |
| Æ÷À塤ÄÚµå´ÜÀ§ |
| ¾àǰ±Ô°Ý |
´ÜÀ§ |
Æ÷ÀåÇüÅ |
´ëÇ¥ÄÚµå |
Ç¥ÁØÄÚµå |
ºñ°í |
| 5¹Ð¸®¸®ÅÍ |
1 °³ |
º´ |
8806449007608 |
8806449007615 |
|
|
| ÁÖ¼ººÐÄÚµå |
184902CLQ
[µ¿ÀÏÇÑ ÁÖ¼ººÐÄڵ带 °¡Áø ¿À¸®Áö³¯ ¶Ç´Â Á¦³×¸¯ ÀǾàǰ Á¶È¸]
|
| Çã°¡»çÇ× ¿ø¹®Á¶È¸ |
[Çã°¡»çÇ× ¿ø¹®Á¶È¸]
|
| È¿´ÉÈ¿°ú |
[ÀûÀÀÁõ º° °Ë»ö]
1. À¯È¿±ÕÁ¾
Æ÷µµ±¸±Õ¼Ó, ¿¬¼â±¸±Õ¼Ó, Àå³»±¸±Õ¼Ó, ¼Ò±¸±Õ¼Ó, ÄÚ¸®³×¹ÚÅ×·ý¼Ó, īŸ¸£¼º ºê¶ó³ª¸á¶ó,
ÇÁ·ÎÇÇ¿À´Ï¹ÚÅ×·ý¤ý¿¡ÀÌÄñ½º, ¹Ù½Ç·¯½º¼Ó, Ŭ·¹ºê½Ã¿¤¶ó¼Ó, ¿£Å׷ιÚÅͼÓ, ¼¼¶óƼ¾Æ¼Ó,
ÇÁ·ÎÅ׿콺¼Ó, ½´µµ¸ð³ª½º¼Ó, Çö󺸹ÚÅ×·ý¼Ó, ÀÎÇ÷翣ÀÚ±Õ, Çì¸ðÇʷ罺¤ý¿¡½ÃµµÇʷ罺
(ÄÚÈ£ ¤ýÀ¨½º±Õ), ¸ð¶ô¼¿¶ó¼Ó, ¾Æ½Ã³×Åä¹ÚÅͼÓ
2. ÀûÀÀÁõ
¾È°Ë¿°, ¸Æ¸³Á¾, ´©³¶¿°, °á¸·¿°, °ËÆÇ¼±¿°, °¢¸·¿°, °¢¸·±Ë¾ç, ¼ö¼úÈÄ °¨¿°Áõ
ÀÌ °ú ¿ë(ì¼ Î¡ éÄ)
1. À¯È¿±ÕÁ¾
Æ÷µµ±¸±Õ¼Ó, ¿¬¼â±¸±Õ¼Ó, Ŭ·¹ºê½Ã¿¤¶ó¼Ó, ¿£Å׷ιÚÅͼÓ, ÇÁ·ÎÅ׿콺¼Ó, ÇÁ·Îºñµ§½Ã¾Æ¼Ó,
½´µµ¸ð³ª½º¼Ó, ¾Æ½Ã³×Åä¹ÚÅͼÓ, ¾ËÄ®¸®°Õ³×½º¼Ó
2. ÀûÀÀÁõ
¿ÜÀÌ¿°, ÁßÀÌ¿°
|
| ¿ë¹ý¿ë·® |
* Àý´ë ÀÓÀǺ¹¿ëÇÏÁö ¸¶½Ã°í ¹Ýµå½Ã ÀÇ»ç ¶Ç´Â ¾à»ç¿Í »ó´ãÇϽñ⠹ٶø´Ï´Ù.
[󹿾à¾î]
¾È°ú¿ë
º¸Åë 1ȸ 1Àû, 1ÀÏ 3ȸ Á¡¾ÈÇÑ´Ù. ¶ÇÇÑ Áõ»ó¿¡ µû¶ó ÀûÀýÈ÷ Áõ°¨ÇÑ´Ù.
À̰ú¿ë
º¸Åë 1ȸ 6-10¹æ¿ïÀ» Á¡ÀÌÇÏ¿©, ¾à 10ºÐµ¿¾È 1ÀÏ 2ȸ¾¿ ÀÌ¿å(ì¼é±)ÇÑ´Ù.
¶ÇÇÑ Áõ»ó¿¡ µû¶ó Ƚ¼ö¸¦ ÀûÀýÈ÷ Áõ°¨ÇÑ´Ù.
|
| ÁÖ¿ä¾à¹° »óÈ£ÀÛ¿ë |
[Á¶È¸]
|
| ±Ý±â |
< ¾È°ú¿ë >
1) ÀÌ ¾à¿¡ ÀÇÇÏ¿© °ú¹ÎÁõÀÇ º´·ÂÀÌ Àִ ȯÀÚ
2) ¼¼±Õ¼º °¢¸·¿° ¶Ç´Â ¾È±¸³»¿° ȯÀÚ(°¢¸·À¸·Î ħÅõ°¡ Á¦ÇÑÀûÀÓ)
< À̰ú¿ë >
ÀÌ ¾à¿¡ ÀÇÇÏ¿© °ú¹ÎÁõÀÇ º´·ÂÀÌ Àִ ȯÀÚ |
| ½ÅÁßÅõ¿© |
´Ù¸¥ Äû³î·Ð°è Ç×±ÕÁ¦¿¡ °ú¹ÎÁõÀÇ º´·ÂÀÌ Àִ ȯÀÚ |
| ÀÌ»ó¹ÝÀÀ |
< ¾È°ú¿ë >
1) °ú¹ÎÁõ : °ú¹ÎÁõ»óÀÌ ³ªÅ¸³ °æ¿ì¿¡´Â Åõ¿©¸¦ ÁßÁöÇÒ °Í
2) ´« : °á¸·ÃæÇ÷, °á¸·¿°, ¶§¶§·Î µû°©°Å³ª µ¿Åë µîÀÇ ÀÚ±ØÁõ»ó, °¡·Á¿òÁõ, ¾È°Ë¿°, °¢¸·¿° µîÀÌ ³ªÅ¸³ª´Â °æ¿ì°¡ ÀÖ´Ù.
3) ±¤°ú¹Î¼ºÀÇ ¹ßÇöµµ °¡´ÉÇÏ´Ù.
4) Àü½ÅÅõ¿©¿¡¼ õ½Ä, È£Èí°ï¶õ, µÎµå·¯±â, È«¹Ý, °¡·Á¿òÁõ, ºñƯÀÌÀû °ú¹Î¹ÝÀÀÀÌ ¹ßÇöµÇ¾úÀ¸¹Ç·Î Á¡¾ÈÁ¦¿¡¼µµ ¹èÁ¦µÉ ¼ö ¾ø´Ù.
< À̰ú¿ë >
1) °ú¹ÎÁõ : °ú¹ÎÁõ»óÀÌ ³ªÅ¸³ °æ¿ì¿¡´Â Åõ¿©¸¦ ÁßÁöÇÒ °Í
2) ±Í : ¶§¶§·Î ¿ÜÀ̵µ °¡·Á¿òÁõ, Á¡À̽à ÀÌÅë, Àڱذ¨, Àϰú¼º û·ÂÀúÇÏ, ±Õ±³´ëÁõ µîÀÌ ³ªÅ¸³ª´Â °æ¿ì°¡ ÀÖ´Ù.
3) ±¤°ú¹Î¼ºÀÇ ¹ßÇöµµ °¡´ÉÇÏ´Ù.
4) Àü½ÅÅõ¿©¿¡¼ õ½Ä, È£Èí°ï¶õ, µÎµå·¯±â, È«¹Ý, °¡·Á¿òÁõ, ºñƯÀÌÀû °ú¹Î¹ÝÀÀÀÌ ¹ßÇöµÇ¾úÀ¸¹Ç·Î Á¡ÀÌÁ¦¿¡¼µµ ¹èÁ¦µÉ ¼ö ¾ø´Ù.
|
| »óÈ£ÀÛ¿ë |
ÇöÀç±îÁö ¾Ë·ÁÁø »óÈ£ÀÛ¿ëÀº ¾øÀ¸³ª ÀÌ ¾à°ú ±¹¼ÒÀû Ç×»ýÁ¦¸¦ µ¿½Ã¿¡ º´¿ëÅõ¿©ÇÏÁö ¾Ê´Â´Ù. |
| Related FDA Approved Drug |
±âÁØ ¼ººÐ: LOMEFLOXACIN HYDROCHLORIDEMAXAQUIN (LOMEFLOXACIN HYDROCHLORIDE)
|
|
|
 | Á¤º¸¿ä¾à |
|
|
|
µå·°ÀÎÆ÷ ÀǾàǰ ¿ä¾à/»ó¼¼Á¤º¸
|
|
 | ÄÚµå ¹× ºÐ·ùÁ¤º¸ |
|
|
| |
|
 | Á¦Ç°Á¤º¸ |
|
|
|
|
 | º¹¾àÁ¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
| LACTmed ¹Ù·Î°¡±â |
[¹Ù·Î°¡±â]
|
| ¾à¸®ÀÛ¿ë |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| Ãà¾àº¹¾àÁöµµ |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| º¹¾àÁöµµ |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| ÀӺο¡´ëÇÑÅõ¿© |
| * |
ÀüüÀӽŠ±â°£º°·Î ¿©·¯µî±ÞÀÌ Á¸ÀçÇÒ ¼ö ÀÖÀ¸¸ç °¡Àå À§Çèµµ°¡ ³ôÀº Á¤º¸¸¸ º¸¿©Áý´Ï´Ù. ´Ü, º¹ÇÕÁ¦ÀÇ °æ¿ì ¸ðµç º¹ÇÕÁ¦¼ººÐ¿¡ ´ëÇÑ ÀÓºÎÅõ¿©µî±ÞÀÌ Ç¥½ÃµÈ°ÍÀº Àý´ë ¾Æ´Ï¸ç Ç¥½ÃµÈ°ÍÁß¿¡ °¡Àå À§Çèµµ°¡ ³ôÀº Á¤º¸¸¸ ³ªÅ¸³³´Ï´Ù.
|
|
|   |
 FDA : Cµî±Þ
|
|
| * |
»ó±â ÀÓºÎÅõ¿©¿¡ ´ëÇÑ Á¤º¸´Â Àü»êó¸® µÇ¸é¼ ÀÔ·Â ¿À·ù °¡´É¼ºÀÌ Á¸ÀçÇÕ´Ï´Ù. ¿À·ù °¡´É¼ºÀ» ÃÖ¼ÒÈÇϱâ À§ÇÏ¿© ¸¹Àº ³ë·ÂÀ» ±â¿ïÀ̰í ÀÖÀ¸³ª, ±× Á¤È®¼º¿¡ ´ëÇÏ¿© È®½ÅÀ» µå¸± ¼ö ¾ø½À´Ï´Ù. ÀÌ¿¡ ´ëÇØ ȸ»ç´Â Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù.
|
| * |
¹Ýµå½Ã °ø½Å·Â ÀÖ´Â ¹®ÇåÀ» ´Ù½Ã Çѹø Âü°í ÇϽñ⠹ٶó¸ç ÀÇ»ç ¶Ç´Â ¾à»çÀÇ ÆÇ´Ü¿¡ µû¶ó Åõ¿©¿©ºÎ°¡ °áÁ¤µÇ¾î¾ß ÇÕ´Ï´Ù.
|
|
|
| Pharmacokinetics |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| º´¿ë±Ý±â ¹× ¿¬·É´ë±Ý±â ±Ù°ÅÁ¶È¸ |
[º´¿ë±Ý±â ¹× ¿¬·É´ë±Ý±â ±Ù°ÅÁ¶È¸]
|
| Á¦Çüº° º¹¾àÁöµµ |
[Á¡¾È¾×] |
| º¸°ü»ó ÁÖÀÇ |
|
| Á¶Á¦½Ã ÁÖÀÇ |
|
|
|
 | ½É»çÁ¤º¸ |
|
|
|
|
 | ÇмúÁ¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
| DUR (ÀǾàǰ»ç¿ëÆò°¡) |
º´¿ë±Ý±â :
°í½ÃµÈ º´¿ë±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
[»óÈ£ÀÛ¿ë/º´¿ë±Ý±â°Ë»ö]
¿¬·É´ë±Ý±â :
°í½ÃµÈ ¿¬·É±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
[¿¬·É´ë±Ý±â»ó¼¼°Ë»ö]
|
| Mechanism of Action |
Lomefloxacin¿¡ ´ëÇÑ Mechanism_Of_Action Á¤º¸ Lomefloxacin is a bactericidal fluoroquinolone agent with activity against a wide range of gram-negative and gram-positive organisms. The bactericidal action of lomefloxacin results from interference with the activity of the bacterial enzymes DNA gyrase and topoisomerase IV, which are needed for the transcription and replication of bacterial DNA. DNA gyrase appears to be the primary quinolone target for gram-negative bacteria. Topoisomerase IV appears to be the preferential target in gram-positive organisms. Interference with these two topoisomerases results in strand breakage of the bacterial chromosome, supercoiling, and resealing. As a result DNA replication and transcription is inhibited.
|
| Pharmacology |
Lomefloxacin¿¡ ´ëÇÑ Pharmacology Á¤º¸ Lomefloxacin is a fluoroquinolone antibiotic used to treat chronic bronchitis, as well as complicated and uncomplicated urinary tract infections. It is also used as a prophylactic or preventative treatment to prevent urinary tract infections in patients undergoing transrectal or transurethral surgical procedures. Flouroquinolones such as lomefloxacin possess excellent activity against gram-negative aerobic bacteria such as E.coli and Neisseria gonorrhoea as well as gram-positive bacteria including S. pneumoniae and Staphylococcus aureus. They also posses effective activity against shigella, salmonella, campylobacter, gonococcal organisms, and multi drug resistant pseudomonas and enterobacter.
|
| Metabolism |
Lomefloxacin¿¡ ´ëÇÑ Metabolism Á¤º¸ # Phase_1_Metabolizing_Enzyme:Cytochrome P450 1A2 (CYP1A2)
|
| Protein Binding |
Lomefloxacin¿¡ ´ëÇÑ ´Ü¹é°áÇÕ Á¤º¸ 10%
|
| Half-life |
Lomefloxacin¿¡ ´ëÇÑ ¹Ý°¨±â Á¤º¸ 8 hours
|
| Absorption |
Lomefloxacin¿¡ ´ëÇÑ Absorption Á¤º¸ Rapid and nearly complete with approximately 95% to 98% of a single oral dose being absorbed.
|
| Pharmacokinetics |
Lomefloxacin HClÀÇ ¾à¹°µ¿·ÂÇÐÀÚ·á
- Èí¼ö : Àß Èí¼öµÈ´Ù.
- ºÐÆ÷ : ºÐÆ÷¿ëÀû : 2.4-3.5 L/kg
- ´Ü¹é°áÇÕ : 20%
- ¹Ý°¨±â : 5-7.5 ½Ã°£
- ¼Ò½Ç : ÁÖ·Î ¹Ìº¯Èü·Î ½Å¹è¼³
|
| Biotransformation |
Lomefloxacin¿¡ ´ëÇÑ Biotransformation Á¤º¸ Minimally metabolized although 5 metabolites have been identified in human urine. 65% appears as the parent drug in urine and 9% as the glucuronide metabolite.
|
| Toxicity |
Lomefloxacin¿¡ ´ëÇÑ Toxicity Á¤º¸ Adverse reactions include peripheral neuropathy, nervousness, agitation, anxiety, and phototoxic events (rash, itching, burning) due to sunlight exposure.
|
| Drug Interactions |
Lomefloxacin¿¡ ´ëÇÑ Drug_Interactions Á¤º¸ Not Available
|
CYP450 Drug Interaction |
[CYP450 TableÁ÷Á¢Á¶È¸]
|
| Drug Target |
[Drug Target]
|
| Description |
Lomefloxacin¿¡ ´ëÇÑ Description Á¤º¸ Lomefloxacin is a fluoroquinolone antibiotic, used to treat bacterial infections including bronchitis and urinary tract infections. It is also used to prevent urinary tract infections prior to surgery.
|
| Dosage Form |
Lomefloxacin¿¡ ´ëÇÑ Dosage_Form Á¤º¸ Tablet Oral
|
| Drug Category |
Lomefloxacin¿¡ ´ëÇÑ Drug_Category Á¤º¸ Anti-Infective AgentsAnti-Infective Agents, UrinaryAntitubercular AgentsPhotosensitizing Agents
|
| Smiles String Canonical |
Lomefloxacin¿¡ ´ëÇÑ Smiles_String_canonical Á¤º¸ CCN1C=C(C(O)=O)C(=O)C2=CC(F)=C(N3CCNC(C)C3)C(F)=C12
|
| Smiles String Isomeric |
Lomefloxacin¿¡ ´ëÇÑ Smiles_String_isomeric Á¤º¸ CCN1C=C(C(O)=O)C(=O)C2=CC(F)=C(N3CCN[C@@H](C)C3)C(F)=C12
|
| InChI Identifier |
Lomefloxacin¿¡ ´ëÇÑ InChI_Identifier Á¤º¸ InChI=1/C17H19F2N3O3/c1-3-21-8-11(17(24)25)16(23)10-6-12(18)15(13(19)14(10)21)22-5-4-20-9(2)7-22/h6,8-9,20H,3-5,7H2,1-2H3,(H,24,25)/f/h24H
|
| Chemical IUPAC Name |
Lomefloxacin¿¡ ´ëÇÑ Chemical_IUPAC_Name Á¤º¸ 1-ethyl-6,8-difluoro-7-(3-methylpiperazin-1-yl)-4-oxoquinoline-3-carboxylic acid
|
|
|
 | »ç¿ëÀÚÄÁÅÙÃ÷ |
|
|
|
|
|
-
ÃÖ±ÙÁ¤º¸¼öÁ¤ÀÏ 2025-10-13
-
º» ¼öÁ¤ÀÏ Á¤º¸´Â Çã°¡Á¤º¸ ÀÌ¿ÜÀÇ ±âŸÁ¤º¸ ¼öÁ¤ÀÏÀ» ÀǹÌÇϹǷÎ, Çã°¡Á¤º¸¼öÁ¤ÀÏÀº º»¹®¿¡ Ç¥±âµÈ ³¯Â¥¸¦ ÂüÁ¶ÇϽñ⠹ٶø´Ï´Ù.
|
|
¾Ë¸² |
»ó¼¼Á¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×À» Åä´ë·Î ÀÛ¼ºµÇ¾úÀ¸¸ç ¿ä¾àÁ¤º¸´Â »ó¼¼Á¤º¸ ¹× ±âŸ¹®ÇåÀ» ±â¹ÝÀ¸·Î µå·°ÀÎÆ÷¿¡¼ ÆíÁýÇÑ ³»¿ëÀÔ´Ï´Ù. Á¦Ç°Çã°¡»çÇ×ÀÇ ¸ñÂ÷¿Í ´Ù¼Ò »óÀÌÇÒ ¼ö ÀÖ½À´Ï´Ù. |
|
°æ°í |
µå·°ÀÎÆ÷ ÀǾàÇмúÁ¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×, Çмú¹®Çå, Á¦¾àȸ»ç Á¦°øÁ¤º¸ µîÀ» ±Ù°Å·Î ÀÛ¼ºµÈ Âü°í Á¤º¸ÀÔ´Ï´Ù.
Á¤º¸ÀÇ Á¤È®¼ºÀ» À§ÇØ ³ë·ÂÇϰí ÀÖÀ¸³ª ÆíÁý»óÀÇ ¿À·ù, Çã°¡»çÇ× º¯°æ, Ãß°¡ÀûÀÎ Çмú¿¬±¸ ¶Ç´Â Àӻ󿬱¸ ¹ßÇ¥ µîÀ¸·Î ÀÎÇØ ¹ß»ýÇÏ´Â ¹®Á¦¿¡ ´ëÇØ µå·°ÀÎÆ÷´Â
Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù. ÀÚ¼¼ÇÑ ³»¿ëÀº ¡°Ã¥ÀÓÀÇ ÇÑ°è ¹× ¹ýÀû°íÁö¡±¸¦ ÂüÁ¶ÇØ ÁֽʽÿÀ.
¹Ýµå½Ã Á¦Á¶¡¤¼öÀÔ»ç, ÆÇ¸Å»ç, ÀÇ»ç, ¾à»ç¿¡°Ô ÃÖÁ¾ÀûÀ¸·Î È®ÀÎÇϽñ⠹ٶø´Ï´Ù.
ÀüÈ: 02-3486-1061 ¤Ó À̸ÞÀÏ: webmaster@druginfo.co.kr
|
|
¾Æ·¡ÀÇ ³»¿ëÀ» Æ÷ÇÔÇÑ Àüü µ¥ÀÌÅ͸¦ º¸½Ã·Á¸é
¿©±â·Î À̵¿ÇϽñ⠹ٶø´Ï´Ù.
º´¿ë±Ý±â ¹× ƯÁ¤¿¬·É´ë ±Ý±â ¼ººÐ
[ÀǾàǰº´¿ë/¿¬·É´ë±Ý±â °í½Ã±Ù°Å·Î ¹Ù·Î°¡±â] Á¦¸ñ ¾øÀ½
2008³â 8¿ù 1ÀÏ ¾à°¡ÈÀÏ»ó 8¿ù´Þ ½Å±ÔµîÀç ¹× »èÁ¦µÇ´Â ǰ¸ñ Æ÷ÇÔÇÑ º´¿ë¿¬·É ±Ý±â ǰ¸ñ¸®½ºÆ® ±âÁØ
1. ÇöÀç °Ë»öÇÑ Á¦Ç°¿¡ ´ëÇÑ º´¿ë±Ý±â Á¦Ç° Á¸Àç¿©ºÎ ¹× °Ë»ö
ÇöÀç ÀÌÁ¦Ç°¿¡ ´ëÇÑ º´¿ë±Ý±â¿¡ ÇØ´çÇϴ û±¸Äڵ庰 Á¦Ç°³»¿ª °øÁö³»¿ëÀÌ ¾ø½À´Ï´Ù
2. ¿¬·É´ë±Ý±â Á¸Àç¿©ºÎ
ÇöÀç ÀÌÁ¦Ç°¿¡ ´ëÇÑ ¿¬·É±Ý±â¿¡ ÇØ´çÇϴ û±¸Äڵ庰 °øÁö³»¿ëÀÌ ¾ø½À´Ï´Ù
|
|
|
|